Simvastatin exerts its anti-inflammatory effect in hypercholesterolaemic patients by decreasing the serum levels of monocyte chemoattractant protein-1

International Journal of Cardiology

Volumn 124, Issue 2, 2008, Pages 271-272

  Rallidis, Loukianos S ^a   Hamodraka, Eftichia S ^b   Fountoulaki, Katerina ^a   Moustogiannis, Georgios ^b   Zolindaki, Maria G ^b   Kremastinos, Dimitrios T ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b GENERAL HOSPITAL OF NIKEA   (Greece)

Author keywords

Hypercholesterolaemia; Inflammatory markers; Monocyte chemoattractant protein 1; Simvastatin

Indexed keywords

INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; SIMVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; COLONY FORMING UNIT M; CONTROLLED STUDY; HUMAN; HYPERCHOLESTEROLEMIA; LIPID DIET; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; AMYLOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHEMOKINE CCL2; CYTOKINES; DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROBABILITY; REFERENCE VALUES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SIMVASTATIN; TREATMENT OUTCOME;

EID: 38649124898     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.12.059     Document Type: Article

References (9)

1. Ikeda U., Matsui K., Murakami Y., and Shimada K. Monocyte chemoattractant protein-1 and coronary artery disease. Clin Cardiol 25 (2002) 143-147
2. Nelken N.A., Coughlin S.R., Gordon D., and Wilcox J.N. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 88 (1991) 1121-1127
3. Rezaie-Majd A., Maca T., Bucek R.A., et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 22 (2002) 1194-1199
4. Xu Z.M., Zhao S.P., Li Q.Z., Nie S., and Zhou H.N. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clin Chim Acta 338 (2003) 17-24
5. Blomqvist H.M., and Olsson A.G. Monocyte chemoattractant protein-1 and CC-chemokine receptor-2 in severe hypercholesterolaemia. Scand J Clin Lab Invest 63 (2003) 513-519
6. Takebayashi K., Matsumoto S., Wakabayashi S., et al. The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia. Metabolism 54 (2005) 1225-1229
7. Wiklund O., Mattsson-Hulten L., Hurt-Camejo E., and Oscarsson J. Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med 251 (2002) 338-347
8. de Lemos J.A., Blazing M.A., Wiviott S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292 (2004) 1307-1316
9. Erikstrup C., Ullum H., and Pedersen B.K. Short-term simvastatin treatment has no effect on plasma cytokine response in a human in vivo model of low-grade inflammation. Clin Exp Immunol 144 (2006) 94-100